- Collaboration combines Nuclera’s eProtein Discovery System, which accelerates protein expression, purification and optimization, with Cytiva’s Biacore SPR system, which characterizes molecular interactions
- Collaboration allows researchers to progress rapidly from DNA to purified and characterized protein, to facilitate insights into drug-target interactions
- Showcased at Discovery on Target and PEGS Europe conferences, detailing the production and characterization of Bruton’s Tyrosine Kinase, which is implicated in B-cell malignancies
CAMBRIDGE, England & MARLBOROUGH, Mass.–(BUSINESS WIRE)–Nuclera, the biotechnology company accelerating protein expression and optimization through its benchtop eProtein Discovery™ System, has announced a collaboration with Cytiva, a global life sciences leader. This collaboration is focused on accelerating the production, purification and characterization of proteins required for drug research and development, enabled through the combination of Nuclera’s eProtein Discovery System with Cytiva’s Biacore™ surface plasmon resonance (SPR) technology.
Proteins represent 95% of drug targets designed to combat disease. Rapid access to these proteins and understanding how they interact with drug candidates is essential for drug development. Typically, it takes months to obtain and characterize proteins, but Nuclera and Cytiva together have achieved production and characterization within five days. This achievement was showcased at industry conferences Discovery on Target and PEGS Europe, where Nuclera’s eProtein Discovery System was used to produce Bruton’s Tyrosine Kinase (BTK) and Vascular Endothelial Growth Factor (VEGF). These proteins were subsequently functionally characterized using Cytiva’s Biacore SPR system.
Dr. Yvonne Tan, Associate Director of Product Management, Nuclera, commented: “Collaborating with life science leader Cytiva supports Nuclera in our mission of improving human health. Through this collaboration, we have demonstrated eProtein Discovery’s ability to produce clinically significant proteins that can be used in characterization experiments. Combining eProtein Discovery’s capability to streamline protein production workflows with Cytiva’s Biacore protein characterization systems open a whole new avenue for accelerating drug development.”
Anna Moberg, Senior Manager and Project Manager, Cytiva, added: “The ability of Nuclera’s eProtein Discovery to accelerate protein production and purification complements Cytiva’s Biacore SPR technology by streamlining the upstream protein production process. We look forward to continuing our collaboration to further enhance the production of characterizable proteins for drug development.”
For more information about Nuclera’s eProtein Discovery System, please visit: https://www.nuclera.com/system/
Contacts
Media contact:
Dr. Ben Rutter
Zyme Communications
Tel: +44(0)7920 770 935
Email: ben.rutter@zymecommunications.com
